Id |
Subject |
Object |
Predicate |
Lexical cue |
T0 |
0-9 |
REG |
denotes |
Targeting |
T1 |
10-27 |
CPA |
denotes |
Neuroinflammation |
T2 |
68-80 |
REG |
denotes |
Modification |
T3 |
84-108 |
DISEASE |
denotes |
Drug-Refractory Epilepsy |
T4 |
123-131 |
DISEASE |
denotes |
epilepsy |
T5 |
184-187 |
NEGREG |
denotes |
not |
T6 |
302-310 |
REG |
denotes |
altering |
T7 |
329-340 |
CPA |
denotes |
progression |
T8 |
357-369 |
CPA |
denotes |
Inflammation |
T9 |
400-407 |
REG |
denotes |
playing |
T10 |
421-425 |
REG |
denotes |
role |
T11 |
451-474 |
CPA |
denotes |
hyperexcitable networks |
T12 |
506-517 |
NEGREG |
denotes |
suppression |
T13 |
529-541 |
CPA |
denotes |
inflammation |
T14 |
600-607 |
NEGREG |
denotes |
prevent |
T15 |
608-623 |
CPA |
denotes |
epileptogenesis |
T16 |
631-636 |
REG |
denotes |
treat |
T17 |
637-661 |
DISEASE |
denotes |
drug-refractory epilepsy |
T18 |
757-767 |
REG |
denotes |
contribute |
T19 |
771-780 |
POSREG |
denotes |
sustained |
T20 |
781-793 |
CPA |
denotes |
inflammation |
T21 |
814-822 |
DISEASE |
denotes |
epilepsy |
T22 |
848-856 |
REG |
denotes |
targeted |
T23 |
858-861 |
GENE |
denotes |
ATP |
T24 |
929-938 |
POSREG |
denotes |
increased |
T25 |
939-956 |
CPA |
denotes |
neuronal activity |
T26 |
1001-1010 |
REG |
denotes |
functions |
T27 |
1016-1022 |
CPA |
denotes |
neuro- |
T28 |
1049-1057 |
MPA |
denotes |
released |
T29 |
1059-1062 |
GENE |
denotes |
ATP |
T30 |
1063-1072 |
POSREG |
denotes |
activates |
T31 |
1134-1137 |
GENE |
denotes |
P2Y |
T32 |
1153-1166 |
GENE |
denotes |
P2X receptors |
T33 |
1168-1175 |
REG |
denotes |
driving |
T34 |
1176-1198 |
CPA |
denotes |
inflammatory processes |
T35 |
1271-1281 |
MPA |
denotes |
expression |
T36 |
1282-1289 |
REG |
denotes |
changes |
T37 |
1298-1301 |
GENE |
denotes |
P2Y |
T38 |
1306-1319 |
GENE |
denotes |
P2X receptors |
T39 |
1327-1335 |
DISEASE |
denotes |
epilepsy |
T40 |
1359-1368 |
REG |
denotes |
targeting |
T41 |
1411-1415 |
GENE |
denotes |
P2Y1 |
T42 |
1420-1424 |
GENE |
denotes |
P2X7 |
T43 |
1454-1461 |
REG |
denotes |
possess |
T44 |
1467-1481 |
CPA |
denotes |
anticonvulsive |
T45 |
1486-1509 |
MPA |
denotes |
antiepileptic potential |
T46 |
1620-1627 |
REG |
denotes |
targets |
T47 |
1632-1640 |
DISEASE |
denotes |
epilepsy |
T48 |
1662-1677 |
REG |
denotes |
receptor-driven |
T49 |
1678-1690 |
CPA |
denotes |
inflammation |
T50 |
1695-1705 |
REG |
denotes |
contribute |
T51 |
1727-1735 |
CPA |
denotes |
seizures |
T52 |
1744-1755 |
CPA |
denotes |
development |
T53 |
1759-1767 |
DISEASE |
denotes |
epilepsy |
R0 |
T0 |
T2 |
CauseOf |
Targeting,Modification |
R1 |
T1 |
T0 |
ThemeOf |
Neuroinflammation,Targeting |
R10 |
T12 |
T14 |
CauseOf |
suppression,prevent |
R11 |
T13 |
T12 |
ThemeOf |
inflammation,suppression |
R12 |
T15 |
T14 |
ThemeOf |
epileptogenesis,prevent |
R13 |
T17 |
T14 |
ThemeOf |
drug-refractory epilepsy,prevent |
R14 |
T17 |
T16 |
ThemeOf |
drug-refractory epilepsy,treat |
R15 |
T19 |
T18 |
ThemeOf |
sustained,contribute |
R16 |
T20 |
T18 |
ThemeOf |
inflammation,contribute |
R17 |
T20 |
T19 |
ThemeOf |
inflammation,sustained |
R18 |
T21 |
T18 |
ThemeOf |
epilepsy,contribute |
R19 |
T21 |
T19 |
ThemeOf |
epilepsy,sustained |
R2 |
T3 |
T0 |
ThemeOf |
Drug-Refractory Epilepsy,Targeting |
R20 |
T21 |
T20 |
ThemeOf |
epilepsy,inflammation |
R21 |
T21 |
T22 |
ThemeOf |
epilepsy,targeted |
R22 |
T25 |
T24 |
ThemeOf |
neuronal activity,increased |
R23 |
T27 |
T26 |
ThemeOf |
neuro-,functions |
R24 |
T28 |
T33 |
CauseOf |
released,driving |
R25 |
T29 |
T30 |
ThemeOf |
ATP,activates |
R26 |
T30 |
T33 |
CauseOf |
activates,driving |
R27 |
T31 |
T30 |
ThemeOf |
P2Y,activates |
R28 |
T32 |
T30 |
ThemeOf |
P2X receptors,activates |
R29 |
T34 |
T33 |
ThemeOf |
inflammatory processes,driving |
R3 |
T3 |
T2 |
ThemeOf |
Drug-Refractory Epilepsy,Modification |
R30 |
T35 |
T36 |
ThemeOf |
expression,changes |
R31 |
T37 |
T35 |
ThemeOf |
P2Y,expression |
R32 |
T37 |
T36 |
ThemeOf |
P2Y,changes |
R33 |
T38 |
T35 |
ThemeOf |
P2X receptors,expression |
R34 |
T38 |
T36 |
ThemeOf |
P2X receptors,changes |
R35 |
T39 |
T35 |
ThemeOf |
epilepsy,expression |
R36 |
T39 |
T36 |
ThemeOf |
epilepsy,changes |
R37 |
T41 |
T40 |
ThemeOf |
P2Y1,targeting |
R38 |
T42 |
T40 |
ThemeOf |
P2X7,targeting |
R39 |
T44 |
T43 |
ThemeOf |
anticonvulsive,possess |
R4 |
T4 |
T5 |
ThemeOf |
epilepsy,not |
R40 |
T45 |
T43 |
ThemeOf |
antiepileptic potential,possess |
R41 |
T47 |
T46 |
ThemeOf |
epilepsy,targets |
R42 |
T49 |
T48 |
ThemeOf |
inflammation,receptor-driven |
R43 |
T49 |
T50 |
ThemeOf |
inflammation,contribute |
R44 |
T51 |
T50 |
ThemeOf |
seizures,contribute |
R45 |
T52 |
T50 |
ThemeOf |
development,contribute |
R46 |
T53 |
T50 |
ThemeOf |
epilepsy,contribute |
R47 |
T53 |
T52 |
ThemeOf |
epilepsy,development |
R5 |
T7 |
T6 |
ThemeOf |
progression,altering |
R6 |
T8 |
T9 |
ThemeOf |
Inflammation,playing |
R7 |
T8 |
T10 |
ThemeOf |
Inflammation,role |
R8 |
T10 |
T9 |
ThemeOf |
role,playing |
R9 |
T11 |
T9 |
ThemeOf |
hyperexcitable networks,playing |